Alexander Pickett is Managing Director at Juvenescence, where he oversees new opportunity sourcing and onboarding. He has been active in Juvenescence since its formation in 2017.

Since 2014, he has has worked with Juvenescence’s founding partners at Mediqventures Ltd, a multi-family investment partnership and merchant bank, where he supported investments in Causeway Therapeutics Ltd., and Portage Biotech Inc., including Biohaven (NYSE:BHVN).  Alexander is currently the Interim Chief Executive Officer at Portage Biotech Inc. (NASDAQ:PRTG), where he is assisting the company through a transition in management.  

Prior to joining Mediqventures, Alexander was an associate at Flatley Venture Capital, a cystic fibrosis-focused investment arm of the John J. Flatley Company, where he was responsible for investment analysis and scientific due diligence. Alexander has a BA in Molecular and Cellular Biology from Harvard College, where he was a Microbial Studies Initiative Undergraduate Fellow and a team member in the International Genetically Engineered Machines Competition.